Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#SUBJECT> ?p ?o ?g. }
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "We" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "the difference" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "Tocilizumab" assertion.
- SUBJECT label "an increase of inhaled oxygen concentration" assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment , and less patients 1/12 , 8.33 % " assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "the hypoxia" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The cure rate in the tocilizumab group" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "The patients" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "More mild temporary adverse events" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "significant influences on the time virus load" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "ELECTRONIC SUPPLEMENTARY Supplementary material" assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment and less patients 1 12 8 33 " assertion.
- SUBJECT label "the hypoxia ameliorated earlier after tocilizumab treatment and less patients 1 12 8 33 " assertion.
- SUBJECT label "The improvement in hypoxia for the tocilizumab group" assertion.
- SUBJECT label "either Tocilizumab" assertion.
- SUBJECT label "to improve outcome" assertion.
- SUBJECT label "Thirty three patients" assertion.
- SUBJECT label "Thirty three patients" assertion.
- SUBJECT label "only one" assertion.
- SUBJECT label "only one" assertion.
- SUBJECT label "HBV reactivation" assertion.
- SUBJECT label "strict monitoring" assertion.
- SUBJECT label "BACKGROUND AND" assertion.
- SUBJECT label "the risk of hepatitis B virus reactivation in patients" assertion.
- SUBJECT label "HBsAg patients" assertion.